title: Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice.
abstract: The previous clinical studies have demonstrated tocilizumab monotherapy to be highly effective in rheumatoid arthritis (RA). The objectives of the present article are to report the efficacy and safety of tocilizumab in patients with active RA in real clinical practice. In total, 61 patients with RA were treated with tocilizumab. Any comorbidities they had, especially infections, were treated thoroughly before they were given the drug. We provided guidance on infection control and prevention. Mean age of the patients was 60.9 +/- 12.4 years, and their mean disease duration 10.9 +/- 9.2 years. The patients remained on steroids, methotrexate, and tacrolimus as before, but were taken off any other drugs they had been using prior to the treatment. Mean of the 28-joint disease activity score using erythrocyte sedimentation rate was 4.75 +/- 1.15 initially and fell to 2.21 +/- 0.97 after two doses (n = 50). After four doses, the remission rate was 83.8% (31/37). All patients responded well to the therapy and there was no decrease in the efficacy of tocilizumab during the treatment. Even in the real clinical setting, treatment with tocilizumab can rapidly induce remission in RA in a high proportion of patients and is generally safe and well tolerated. Tocilizumab would seem to be promising as a first-line choice for the treatment of RA.
authors.affiliation: Department of Rheumatology, Hikarigaoka Spellman Hospital, 6-7-1 Higashisendai, Miyagino-ku, Sendai 983-0833, Japan. y_hirabayashi@doctor.nifty.jp
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Hirabayashi
authors.forename: Tomonori
authors.initials: T
authors.lastname: Ishii
authors.forename: Hideo
authors.initials: H
authors.lastname: Harigae
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology; D015897:Comorbidity; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C502936:tocilizumab
references.citation: Arthritis Rheum. 2007 Dec;56(12):3928-39
references.pmid: 18050208
references.citation: Lancet. 2008 Mar 22;371(9617):987-97
references.pmid: 18358926
references.citation: Ann Rheum Dis. 1998 Jun;57(6):350-6
references.pmid: 9771209
references.citation: BMC Musculoskelet Disord. 2008 Apr 17;9:52
references.pmid: 18419803
references.citation: Best Pract Res Clin Rheumatol. 2006 Jun;20(3):419-33
references.pmid: 16777574
references.citation: J Am Geriatr Soc. 2002 Mar;50(3):430-3
references.pmid: 11943036
references.citation: J Clin Invest. 2008 Nov;118(11):3537-45
references.pmid: 18982160
references.citation: J Periodontol. 2009 Apr;80(4):535-40
references.pmid: 19335072
references.citation: Cancer Res. 1993 Feb 15;53(4):851-6
references.pmid: 8428365
references.citation: Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Feb;105(2):173-9
references.pmid: 17905606
references.citation: J Clin Invest. 2004 May;113(9):1271-6
references.pmid: 15124018
references.citation: Ann Rheum Dis. 2007 Sep;66(9):1162-7
references.pmid: 17485422
references.citation: Biol Pharm Bull. 2007 Nov;30(11):2001-6
references.pmid: 17978466
references.citation: Ann Rheum Dis. 2009 Oct;68(10):1580-4
references.pmid: 19019888
references.citation: Mod Rheumatol. 2009;19(1):12-9
references.pmid: 18979150